Exicure, Inc. (XCUR)

NASDAQ: XCUR · IEX Real-Time Price · USD
1.47
+0.06 (4.26%)
At close: Sep 28, 2022 3:59 PM
1.49
+0.02 (1.36%)
After-hours: Sep 28, 2022 5:34 PM EDT
4.26%
Market Cap 7.29M
Revenue (ttm) 3.48M
Net Income (ttm) -53.17M
Shares Out 4.96M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Jun 30, 2022
Volume 55,761
Open 1.36
Previous Close 1.41
Day's Range 1.36 - 1.57
52-Week Range 1.36 - 39.00
Beta 1.18
Analysts Sell
Price Target 2.04 (+38.8%)
Earnings Date Nov 17, 2022

About XCUR

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease a... [Read more...]

Industry Biotechnology
Founded 2011
CEO David Giljohann
Employees 39
Stock Exchange NASDAQ
Ticker Symbol XCUR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for XCUR stock is "Sell." The 12-month stock price forecast is 2.04, which is an increase of 38.78% from the latest price.

Price Target
$2.04
(38.78% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Imp...

CHICAGO--(BUSINESS WIRE)--Exicure announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.

2 days ago - Business Wire

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

CHICAGO--(BUSINESS WIRE)--Exicure CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference.

3 weeks ago - Business Wire

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

CHICAGO--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended June 30, 2022 and provided an update on its business strategy and corporate progress.

1 month ago - Business Wire

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic an...

2 months ago - Business Wire

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock...

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic an...

2 months ago - Business Wire

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic an...

4 months ago - Business Wire

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

CHICAGO--(BUSINESS WIRE)--Exicure today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference.

4 months ago - Business Wire

Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress

CHICAGO--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress.

4 months ago - Business Wire

Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium

CHICAGO--(BUSINESS WIRE)--Exicure, Inc.® (NASDAQ:XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic an...

4 months ago - Business Wire

Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.

4 months ago - Business Wire

Exicure Shares Plunge After Q4 Results Included A Going Concern Risk

Exicure Inc (NASDAQ: XCUR) has reported year-end cash, cash equivalents, and short-term investments of $48.3 million that will fund its current operations into Q4 of 2022. The Company said that it expec...

6 months ago - Benzinga

Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported full year financial re...

6 months ago - Business Wire

Did You Acquire (XCUR) Before January 7, 2021? Should Management Be Held Accountable for Investors Losses?

San Diego, California--(Newsfile Corp. - February 17, 2022) - Johnson Fistel, LLP is investigating potential claims on behalf of Exicure, Inc. ("Exicure" or the "Company") (NASDAQ: XCUR) against certain...

7 months ago - Newsfile Corp

Exicure Shareholder Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Exicure To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Cor...

7 months ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exicure, Inc. - XCUR

New York, New York--(Newsfile Corp. - February 10, 2022) -  Pomerantz LLP is investigating claims on behalf of investors of Exicure, Inc. ("Exicure" or the "Company") (NASDAQ: XCUR). Such investors are ...

7 months ago - Newsfile Corp

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exicure, I...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 11, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investo...

7 months ago - Business Wire

Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Cont...

Los Angeles, California--(Newsfile Corp. - February 10, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exicure, Inc. ("Ex...

7 months ago - Newsfile Corp

XCUR FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Exicure, Inc. Investors to Secure Counsel Before I...

New York, New York--(Newsfile Corp. - February 10, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Exicure, Inc. (NASDAQ: XCUR) between March 11, ...

7 months ago - Newsfile Corp

Deadline Friday Notice: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact ...

Los Angeles, California--(Newsfile Corp. - February 9, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exicure, Inc. ("Ex...

7 months ago - Newsfile Corp

Deadline Friday Alert: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact T...

Los Angeles, California--(Newsfile Corp. - February 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exicure, Inc. ("Exi...

7 months ago - Newsfile Corp

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. (XCUR) ...

LOS ANGELES, Feb. 7, 2022 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Exi...

7 months ago - PRNewsWire

Friday Deadline Reminder: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contac...

Los Angeles, California--(Newsfile Corp. - February 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exicure, Inc. ("Exi...

7 months ago - Newsfile Corp

Exicure Class Action Reminder

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Exicure To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Cor...

7 months ago - Newsfile Corp

Glancy Prongay & Murray LLP Expands Class Period in the Securities Fraud Lawsuit Against Exicure, Inc. (XCUR)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed an amended class action complaint in the United States District Court for the Northern District of Illinois...

7 months ago - Business Wire

Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors

7 months ago - Business Wire